Tacrine (1) was the first acetylcholinesterase inhibitor (AChEI) approved for the treatment of AD, in 1997, but showed limitations due to hepatotoxic side effects and was later withdrawn in 2013 [8]. This evidence concerns the gene ACHE and Alzheimer disease.